Epha2 antibodies

An immunoconjugate, comprising:

• a) an antibody that binds to ephrin receptor A2 (EphA2), wherein the antibody comprises:
• a variable heavy chain (VH) region comprising amino acid sequence SEQ ID NO:
• 607 and a variable light chain (VL) region comprising amino acid sequence SEQ ID NO:
• 672;
• a VH region comprising amino acid sequence SEQ ID NO:
• 652 and a VL region comprising amino acid sequence SEQ ID NO:
• 717;
• a VH region comprising amino acid sequence SEQ ID NO:
• 67 and a VL region comprising amino acid sequence SEQ ID NO:
• 78;
• a VH region comprising amino acid sequence SEQ ID NO:
• 68 and a VL region comprising amino acid sequence SEQ ID NO:
• 79;
• a VH region comprising amino acid sequence SEQ ID NO:
• 69 and a VL region comprising amino acid sequence SEQ ID NO:
• 80;
• a VH region comprising amino acid sequence SEQ ID NO:
• 70 and a VL region comprising amino acid sequence SEQ ID NO:
• 81;
• a VH region comprising amino acid sequence SEQ ID NO:
• 71 and a VL region comprising amino acid sequence SEQ ID NO:
• 82;
• a VH region comprising amino acid sequence SEQ ID NO:
• 72 and a VL region comprising amino acid sequence SEQ ID NO:
• 83;
• a VH region comprising amino acid sequence SEQ ID NO:
• 73 and a VL region comprising amino acid sequence SEQ ID NO:
• 84;
• a VH region comprising amino acid sequence SEQ ID NO:
• 74 and a VL region comprising amino acid sequence SEQ ID NO:
• 85;
• a VH region comprising amino acid sequence SEQ ID NO:
• 75 and a VL region comprising amino acid sequence SEQ ID NO:
• 86;
• a VH region comprising amino acid sequence SEQ ID NO:
• 76 and a VL region comprising amino acid sequence SEQ ID NO:
• 87;
• or
• a VH region comprising amino acid sequence SEQ ID NO:
• 77 and a VL region comprising amino acid sequence SEQ ID NO:
• 88;
• and
• b) a topoisomerase I inhibitor conjugated to the antibody using a linker.